TrialFind
Saved trials

Filters

Status

Phase

Age group

TrialFind

Data sourced from ClinicalTrials.gov. Always consult a healthcare provider before enrolling.

PrivacyData sourcesRegulatory infoContact
Not yet recruitingN/A

Sleep Interventions and Neurocognitive Outcomes

This protocol focuses on the effect of sleep interventions on improving sleep and building cognitive/brain resilience in older adults with amnestic mild cognitive impairment and sleep disturbance. Two sleep interventions, cognitive behavior

New York, New York, United StatesView details
CompletedN/A

Coaching for Cognition in Alzheimer's (COCOA)

One major study objective is, using 2 study arms (data-driven health coaching plus RC vs. RC only), to evaluate the efficacy of data-driven health coaching.

Newport Beach, California, United StatesView details
CompletedPhase 1

Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid

The study is carried out in order to investigate if \[11C\]AZD2995, compared to \[11C\]AZD2184, is a more suitable PET ligand for in vivo imaging of β amyloid depositions in the human brain. In the study the two PET ligands will be examined

Stockholm, SwedenView details
RecruitingN/A

COGSCREEN II: Early Detection of Cognitive Impairment

While knowledge about dementia and its causes is increasing rapidly, healthcare systems remain ill-equipped to detect cognitive decline in the early stages of neurodegenerative diseases such as Alzheimer's disease (AD). However, improving t

München, GermanyView details
Unknown

[18F]Florbetazine ([18F]92) for Beta Amyloid PET Imaging in Alzheimer's Disease

\[18F\]Florbetazine (\[18F\]92) is a molecularly targeted imaging agent for Aβ protein with a novel diaryl-azine scaffold. It has shown specific binding affinity to Aβ aggregates in postmortem human AD brains and excellent brain pharmacokin

Beijing, ChinaView details
TerminatedPhase 1

A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)

The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY2599666 in different groups of people - those who are healthy, those who have mild cognitive impairment due to Alzheimer's Disease (AD),

Glendale, California, United States+4 moreView details
Unknown

Health and Aging Brain Study: Health Disparities Tau Positron Emission Tomography (PET) Scan Study

The purpose of this project is to study the aging brain among participants enrolled in the Health and Aging Brain Study: Health Disparities project . There are a number of things that can influence how people think as they age, including di

Fort Worth, Texas, United StatesView details
Completed

Functional Magnetic Resonance Imaging (fMRI) of Anosognosia in Amnestic Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD)

This is a three year fMRI study conducted at the University of Wisconsin (UW) Hospital and the William. S.

Madison, Wisconsin, United StatesView details
Unknown

Assessment of Clinical Trial Experiences of Alzheimer's Disease Patients

Taking part in medical trials usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups.

Multiple locationsView details
Recruiting

Biomarker-Integrated Digital Guidance for Early Alzheimer's Detection (BRIDGE-AD): A Nationwide Multicenter Study

The investigators propose a stepwise screening approach. The first step involves rapid digital pre-screening of cognitive function through three components: the SCD-9 questionnaire to capture subjective cognitive complaints, a digital cogni

Beijing, China+5 moreView details
UnknownN/A

Spatial and Ocular Trajectories for the Early Diagnosis of Alzheimer's Disease.

Spatial navigation is a high-level cognitive function that enables humans to orientate themselves and move around in space by constructing a mental representation of the environment. It is particularly interesting because it involves numero

Villeurbanne, Lyon, France+2 moreView details
TerminatedN/A

A Lexico-semantic Program on Tactile Tablet for Patients With Alzheimer's Disease

Lexical semantic disorders are described in Alzheimer's disease, and their incidence in everyday life is important to the extent that these disorders affect expression and comprehension. Providing a tactile tablet stimulation, independent a

Paris, France+1 moreView details
RecruitingN/A

Transcranial Magnetic Stimulation to Slow Down Cognitive Decline in Alzheimer's Disease

New amyloid-targeting drugs for Alzheimer's disease (AD) offer minimal or unclear efficacy and often cause adverse events, highlighting the need for new therapies. In recent years, repetitive transcranial magnetic stimulation (rTMS) has sho

Amsterdam, NetherlandsView details
CompletedPhase 1 / Phase 2

Effect of Elderberry Juice on Cognition and Inflammation in Patients With Mild Cognitive Impairment

Elderberries (Sambuci fructus) have been shown in a number of studies to have significant anti-inflammatory and antioxidant effects. Multiple human and animal studies have supported the anti-inflammatory and antioxidant effects of elderberr

Columbia, Missouri, United StatesView details
Completed

Long-term Follow-up of Cognitive and Functional Evolutions of Persons With Isolated Cognitive Complaints or Mild Cognitive Deficits

Dementia is a clinical syndrome that is the result of distinct underlying pathologies including Alzheimer's disease (AD). Despite more than two decades of research on prevention and treatment of dementia and aging-related cognitive decline,

Amiens, France+25 moreView details
CompletedPhase 2

A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's

The purpose of this trial is to compare the average change in the amount of amyloid beta species in blood after an infusion of solanezumab.

St Louis, Missouri, United StatesView details
Active, not recruiting

Plasma Hydrogen Sulfide as a Biomarker for Alzheimer's Disease and Related Dementias

Hydrogen sulfide is a signaling molecule that is important for vascular health. Because vascular factors such as hypertension and high cholesterol are risk factors for Alzheimer's disease and related dementias, we hypothesize that hydrogen

Shreveport, Louisiana, United StatesView details
RecruitingN/A

Brain Energy for Amyloid Transformation in Alzheimer's Disease Study

The Brain Energy for Amyloid Transformation in AD (Alzheimer's disease) or BEAT-AD study will compare the effects of a ketogenic low-carbohydrate diet and a low-fat diet in adults with mild cognitive impairment. The data collected will help

Winston-Salem, North Carolina, United StatesView details
CompletedPhase 2

DHA Brain Delivery Trial

Carrying the APOE ɛ4 allele is the strongest genetic risk factor for developing Alzheimer's disease. The goal of this project is to identify whether carrying the APOE ɛ4 allele is associated with reduced delivery of DHA to the brain.

Los Angeles, California, United StatesView details
CompletedPhase 1

A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease

This study involves single and multiple doses of LY3202626 and will evaluate the effects of LY3202626 on the body. There will be 4 parts to this study.

Glendale, California, United StatesView details
Load more trials